FDA Approves Inovio's Voceryq, First U.S. DNA Medicine

The U.S. FDA has granted accelerated approval to Inovio Pharmaceuticals' Voceryq (INO-3107), a DNA medicine designed to reduce the frequency of surgeries for adults with recurrent respiratory papillomatosis. This marks the first U.S. FDA-approved DNA medicine, potentially offering a new therapeutic approach for patients.